XLV, the Health Care Select Sector SPDR ETF, enters the first week of June in a quietly conflicted state: short interest has grown steadily for a month, yet options positioning has rotated sharply away from the defensive extremes seen just weeks ago.
The short positioning story is the most notable development right now. Bearish bets have climbed 19% over the past month to 4% of the float — around 10.5 million shares — and rose a further 5.4% in just the past week. That one-month build is meaningful for a broad healthcare ETF that typically attracts short interest as a hedge rather than a directional bet. The acceleration from early May is clear: short share counts were running near 7.5–8 million for most of that month before stepping up sharply after May 8. Cost to borrow has moved with it, nearly doubling over the past week to 0.43% — still low in absolute terms, but a directional signal that demand for borrows is rising. Availability remains very comfortable at roughly 529%, meaning there is no squeeze pressure anywhere in the lending pool; this looks like fresh hedging rather than a scramble for inventory.
The options picture tells the opposite story, and the contrast is sharp. Put/call ratios were running near 2.2 in late April — deeply defensive, at levels close to the 52-week high of 2.67 — and have since compressed to 1.30. That is still above the 52-week low of 0.47, but the z-score is now modestly negative at -0.67, meaning options traders have stepped back from the extreme downside protection they were buying earlier this spring. The easing of the PCR happened almost in lockstep with the mid-May rally in healthcare equities, which saw XLV climb roughly 1% from late April. The divergence is worth watching: options fear has unwound, while short interest has quietly rebuilt.
The institutional ownership base is stable. Managed Account Advisors remains the largest holder at 8.6% of shares, adding nearly 2.9 million shares in the most recent reporting period to end-March. JPMorgan, the second-largest holder at 6.3%, trimmed by roughly 1 million shares over the same period. Morgan Stanley and several broker-dealer platforms also made small reductions, suggesting some rotation out of the fund even as at least one major adviser was adding. The net read is steady rather than either accumulating or distributing aggressively.
The ORTEX short score has edged higher over the past two weeks, moving from around 33 in late May to 39 now — still in moderate territory, not flashing an extreme signal. The score's gradual climb mirrors the pace of the short interest rebuild and reinforces the picture of a measured, deliberate hedge being put on rather than any urgent conviction bet. Price has dipped 1.4% on the week to $146.40, reversing some of the May gains; the month is still marginally positive at +0.85%. Prior distribution events tied to this fund — the quarterly cash dividends, the last paid at $0.59 in March 2026 — tend not to be market-moving, but the ex-date calendar is worth noting if yield is a factor in institutional decisions around the fund.
The setup heading further into June is one of moderating options hedges running alongside a still-building short position — two signals pointing in different directions, with availability so deep that the short builders face no friction whatsoever in maintaining or growing those positions.
See the live data behind this article on ORTEX.
Open XLV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
